spacer
home > epc > spring 2002 > editor's letter
PUBLICATIONS
European Pharmaceutical Contractor

Editor's Letter

In 1988 I edited the very first edition of the Technomark Register. At that time we decided to generate two volumes - one for the UK and Ireland and the other for what we chose to call internally 'the rest of Europe'. We set ourselves the objective of including a minimum of 100 CROs as we felt that there was that number of companies in each of the territories. And what a struggle it was. In the end we hit target for the UK, although looking back we did bend the rules a bit by including a few 'one man bands' to make up numbers. A few months later we managed to achieve the same objective for the European volume. I did not calculate the total annual revenue for the companies at that time, but I would be surprised if the total for the whole of Europe was in excess of US$400 million, with a similar figure for North America - effectively at that time 'the rest of the world'. In the 14 years since the first

publication, the market has grown 20-fold to a figure that we estimate to be US$8 billion.
This figure is calculated from the figures reported in the latest editions of the Technomark Register that we have recently published. No longer do we struggle to find 100 companies, no longer do we bend the inclusion rules to make up the numbers. No, we include over 1,500 companies in 40 countries in a mammoth series of volumes that weigh in at over 10kg and occupy 30cm on my bookshelf. (For a detailed discussion of the global CRO market see the article by Marianne O'Neill and myself). It is of constant wonder to me that a market of this sort of scale and scope is as little known and researched as the CRO market. EPC is one of a handful of publications that concentrate exclusively on the CRO scene while books and market research reports are very few and far between. That a market of vital importance to the pharmaceutical industry receives so little attention remains a mystery to me - thank goodness for EPC!


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Graham Hughes
spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI MEA expert:growing domestic manufacturing is creating new opportunities for international Pharma in the Middle East

Abu Dhabi, 5th August 2019: CPhI Middle East expert Emad Shabbir, Director at EMAD Trade House, states favorable conditions and legislative regulations in Saudi Arabia are resulting in a boom of manufacturers and CMOs partnerships with international pharma companies. With the strategic cooperation between regional generic companies and multinational pharma companies, driving increased local production.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement